BT-1718

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameBT-1718
Drug Alias NameBDC-17BT-1718
ClassificationSmall molecules > Synthetic peptide > Peptide drug conjugate (PDC)
Mechanisms of ActionMatrix metalloproteinase-1 modulators
TargetsMatrix metalloproteinase-1
Therapy Area/IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungEsophageal Neoplasms +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited Kingdom
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesBicycle Therapeutics
China Registration ClassN/A

Develop Information

Active CompaniesBicycle Therapeutics
Inactive CompaniesN/A
Active IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungEsophageal Neoplasms +[5] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A